Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Rudick

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|August 16, 2005
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patientsBianca Weinstock-Guttman, Monika Baier, Youngmin Park, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Annals of Clinical and Translational Neurology|November 25, 2022
Associations of sNfL with clinico-radiological measures in a large MS populationElias S Sotirchos, Kathryn C Fitzgerald, Carol M Singh, et al.
The Journal of Clinical Investigation|February 28, 2023
Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilegeYinghua Ma, David Sannino, Jennifer R Linden, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2017
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disabilityNicholas G LaRocca, Lynn D Hudson, Richard Rudick, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|August 16, 2005
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patientsBianca Weinstock-Guttman, Monika Baier, Youngmin Park, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Annals of Clinical and Translational Neurology|November 25, 2022
Associations of sNfL with clinico-radiological measures in a large MS populationElias S Sotirchos, Kathryn C Fitzgerald, Carol M Singh, et al.
The Journal of Clinical Investigation|February 28, 2023
Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilegeYinghua Ma, David Sannino, Jennifer R Linden, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2017
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disabilityNicholas G LaRocca, Lynn D Hudson, Richard Rudick, et al.
Pageof 3